April 07, 2015 – Aquinox Pharmaceuticals Inc.
Aquinox Pharmaceuticals to Present at 14th Annual Needham Healthcare Conference
VANCOUVER, British Columbia, April 7, 2015 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox”) (Nasdaq:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox’s President & CEO, will present a corporate overview at the upcoming 14th Annual Needham Healthcare Conference on Tuesday, April 14th at 4:20 PM Eastern Time. The conference will take place at the The Westin Grand Central Hotel in New York, NY.
A live audio webcast and archive of the event will be available at: http://www.com/webcast/needham71/aqxp
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of Aquinox’s website. The corporate overview being presented will be available at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox’s lead drug candidate, AQX- 1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. Having successfully completed multiple preclinical studies and clinical trials with AQX-1225, Aquinox is now advancing through Phase 2 development. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Senior Manager, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.629.9223 Ext. 109
Communications Contact Info:
Senior Account Executive
MacDougall Biomedical Communications